Outrage Over Dapagliflozin Withdrawal for Type 1 Diabetes in EU

The voluntary withdrawal of the type 1 diabetes indication for dapagliflozin in the EU by AstraZeneca has been branded as 'appalling' and 'devastating', with questions raised as to why it was pulled.
Medscape Medical News

source https://www.medscape.com/viewarticle/964844?src=rss